KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

Also called NCT03236246

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 206 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03236246
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03236246. Randomized; no masking; primary purpose treatment. Start 2017-08-15 (actual); primary completion 2019-08-30 (actual). Results posted on 2021-03-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)
Acronym
COMPASS
Condition
Chronic Kidney Diseases
Condition
Iron Deficiency Anemia
Intervention (Drug)
KRX-0502
Lead sponsor
Keryx Biopharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct03236246
Content hash
2e1e045e6b033486124e55ecc8fcafd79b2c9e8aa37e4b3cfc1c0bf690d8b789